Latest News and Press Releases

Dublin, Aug. 09, 2024 (GLOBE NEWSWIRE) -- The "Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering. Anti TIGIT...

Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "Global LAG-3 Inhibitors Market, Drug Sales & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering. In recent...

SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the Company has opened enrollment in the HARMONY Study, a global, randomized pivotal Phase 3...

Dublin, Nov. 21, 2023 (GLOBE NEWSWIRE) -- The "US Clinical Trial Data Management Service Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering. The US...

Dublin, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The "Global Progressive Supranuclear Palsy Clinical Trial Pipeline Highlights - 2022" report has been added to ResearchAndMarkets.com's offering.This...

Dublin, Feb. 02, 2023 (GLOBE NEWSWIRE) -- The "Global Hemophilia A Clinical Trial Pipeline Highlights - 2022" report has been added to ResearchAndMarkets.com's offering.The report Hemophilia A...

Top-line Data Readout Remains on Track for early Q4 2019 LOS ANGELES, July 02, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...

Additional Data Describes Novel Clinical Symptom Assessment Tool Developed in Phase 2b Trial and to be Used in Upcoming Phase 3 Clinical Trial LOS ANGELES, June 05, 2018 (GLOBE NEWSWIRE) -- Ritter...

BETHESDA, Md. and DEERFIELD, Ill., Dec. 17, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") and its development and commercialization partner Takeda Pharmaceuticals...

BETHESDA, Md. and DEERFIELD, Ill., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") and its development and commercialization partner Takeda Pharmaceuticals...